Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas

Journal of Neuro-Oncology

Volumn 127, Issue 1, 2016, Pages 23-32

  Nakashima, Shinji ^a   Sugita, Yasuo ^a   Miyoshi, Hiroaki ^a   Arakawa, Fumiko ^a   Muta, Hiroko ^a   Ishibashi, Yukinao ^a   Niino, Daisuke ^a   Ohshima, Koichi ^a   Terasaki, Mizuhiko ^a   Nakamura, Yukihiko ^a   Morioka, Motohiro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; Endothelin B receptor; Glioma; Immune escape mechanism

Indexed keywords

ENDOGLIN; ENDOTHELIN B RECEPTOR; ISOCITRATE DEHYDROGENASE; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; PERIVASCULAR SPACE; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; BRAIN TUMOR; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; IMMUNOLOGY; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BIOMARKERS, TUMOR; BLOTTING, WESTERN; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ENDOTHELIN B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 84959341382     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-2017-5     Document Type: Article

References (38)

1. Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415
2. Inoue A, Yanagisawa M, Kimura S et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863–2867
3. Ahmed SI, Thompson J, Coulson JM, Woll PJ (2000) Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22:422–431
4. Rosano L, Varmi M, Salani D et al (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61:8340–8346
5. Kusuhara M, Yamaguchi K, Nagasaki K et al (1990) Production of endothelin in human cancer cell lines. Cancer Res 50:3257–3261
6. Nelson JB, Chan-Tack K, Hedican SP et al (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663–668
7. Shankar A, Loizidou M, Aliev G et al (1998) Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 85:502–506
8. MacCumber MW, Ross CA, Snyder SH (1990) Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci USA 87:2359–2363
9. Giaid A, Gibson SJ, Herrero MT et al (1991) Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurones of the human brain. Histochemistry 95:303–314
10. Sone M, Takahashi K, Totsune K et al (2000) Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cells. J Cardiovasc Pharmacol 36:S390–S392
11. Shen C, Yang L, Yuan X (2011) Endothelin B receptor expression in human astrocytoma: association with clinicopathological variables and survival outcomes. Int J Neurosci 121:626–631
12. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G (2009) Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 15:4521–4528
13. Buckanovich RJ, Facciabene A, Kim S et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14:28–36
14. Floess S, Freyer J, Siewert C et al (2007) Epigenetic control of the Foxp3 locus in regulatory T cells. PLoS Biol 5:e38
15. Ohkura N, Hamaguchi M, Morikawa H et al (2012) T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37:785–799
16. Ponzoni M, Berger F, Chassagne-Clement C et al (2007) Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 138:316–323
17. Wang JJ, Sun XC, Hu L et al (2013) Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: tissue microarray analysis and association with prognostic significance. Head Neck 35:1719–1725
18. Sugita Y, Takase Y, Mori D, Tokunaga O, Nakashima A, Shigemori M (2007) Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival. J Neurooncol 82:249–256
19. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114(2):97–109
20. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in glioma. N Engl J Med 360:765–773
21. Yamada T, Ohtani S, Sakurai T et al (2006) Reduced expression of the endothelin receptor type B gene in piebald mice caused by insertion of a retroposon-like element in intron 1. J Biol Chem 281:10799–10807
22. Komatani H, Sugita Y, Arakawa F, Ohshima K, Shigemori M (2009) Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int J Oncol 34:665–672
23. Naidoo V, Naidoo S, Mahabeer R, Raidoo DM (2005) Localization of the endothelin system in human diffuse astrocytomas. Cancer 104:1049–1057
24. Koseki C, Imai M, Hirata Y, Yanagisawa M, Masaki T (1989) Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol 256:R858–R866
25. Liu J, Chen R, Casley DJ, Nayler WG (1990) Ischemia and reperfusion increase 125I-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol 258:H829–H835
26. Fujimori A, Yanagisawa M, Saito A et al (1990) Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage. Lancet 336:633
27. Yao Y, Kubota T, Takeuchi H et al (2005) Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25:201–206
28. Behrem S, Zarkovic K, Eskinja N et al (2005) Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 45:417–422
29. Sugita Y, Terasaki M, Nakashima S et al (2015) The perivascular microenvironment in primary central nervous system lymphomas: the role of chemokines and the endothelin B receptor. Brain Tumor Pathol 32:41–48
30. Felgar RE, Macon WR, Kinney MC, Roberts S, Pasha T, Salhany KE (1997) TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 150:1893–1900
31. Mruk DD, Xiao X, Lydka M, Li MW, Bilinska B, Cheng CY (2013) Intercellular adhesion molecule 1: recent findings and new concepts involved in mammalian spermatogenesis. Semin Cell Dev Biol 29:43–54
32. Grimmig T, Kim M, Germer CT, Gasser M, Waaga-Gasser AM (2013) The role of Foxp3 in disease progression in colorectal cancer patients. Oncoimmunology 2:e24521
33. Wainwright DA, Balyasnikova IV, Chang AL et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110–6121
34. + T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178:6840–6848
35. Aguilar LK, Guzik BW, Aguilar-Cordova E (2011) Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112:1969–1977
36. Kawakami Y, Yaguchi T, Sumimoto H et al (2013) Improvement of cancer immunotherapy by combining molecular targeted therapy. Front Oncol 3(136):1–7
37. Terasaki M, Shibui S, Narita Y et al (2011) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337–344
38. Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828